Assessment of test-retest reproducibility of [18F]SynVesT-1, a novel radiotracer for PET imaging of synaptic vesicle glycoprotein 2A
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Purpose Synaptic abnormalities are associated with many brain disorders. Recently, we developed a novel synaptic vesicle glycoprotein 2A (SV2A) radiotracer [18 F]SynVesT-1 and demonstrated its excellent imaging and binding properties in nonhuman primates. The aim of this study was to perform dosimetry calculations in nonhuman primates and to evaluate this tracer in humans and assess its test-retest reliability in comparison with [11 C]UCB-J.Methods Three rhesus monkeys underwent whole body dynamic PET scanning to estimate the absorbed dose. PET scans in six healthy human subjects were acquired. Time-activity curves (TACs) were generated with defined regions of interest (ROI). Reproducibility of distribution volume (V T) values and its sensitivity to scan duration were assessed with the one-tissue compartment (1TC) model. Non-displaceable binding potential (BP ND) was calculated using centrum semiovale as the reference region.Results The dosimetry study showed high uptake in the urinary bladder and brain. In humans, [18 F]SynVesT-1 displayed high uptake with maximum SUV of ~10 and appropriate kinetics with a quick rise in tracer uptake followed by a gradual clearance. Mean 1TC V T values (mL/cm 3) ranged from 3.4 (centrum semiovale) to 19.6 (putamen) and were similar to those of [11 C]UCB-J. Regional BP ND values were 2.7-4.7 in gray matter areas, and mean BP ND values across all ROIs were ~ 21% higher than those of [11 C]UCB-J. The absolute test-retest variability of V T and BP ND was excellent (< 9%) across all brain regions.Conclusions [18 F]SynVesT-1 demonstrates outstanding characteristics in humans: fast and high brain uptake, appropriate tissue kinetics, high levels of specific binding, and excellent test-retest reproducibility of binding parameters. As such, [18 F]SynVesT-1 is proved to be a favorable radiotracer for SV2A imaging and quantification in humans.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In humans, [ 18 F]SynVesT-1 displayed outstanding characteristics, i.e., very high brain uptake, fast and reversible kinetics, excellent test-retest reproducibility and binding specificity to SV2A”
From Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression (2025) · cites this paper as [124]
In the citing paper
“Excellent test-retest reproducibility and low noise V T images can be obtained”
From Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression (2025) · cites this paper as [124]
Citations
Cites
Tzourio-Mazoyer, N., Landeau, B., Papathanassiou, D., Crivello, F., Etard, O., Delcroix, N., Mazoyer, B., & Joliot, M. (2002) · NeuroImage · doi:10.1006/nimg.2001.0978 · Cited by 16,319 · cited 1×
“The summed PET image was then co-registered to the subject’s T1weighted MR image (6-parameter affine registration), which was subsequently co-registered to the automated anatomical labeling (AAL) template [30] in Montreal Neurological Institute (MNI) [31] space using a nonlinear transformation (Bioimage suite) [32].”
MethodSchizophrenia risk from complex variation of complement component 4
Sekar, A., Bialas, A. R., de Rivera, H., Davis, A., Hammond, T. R., Kamitaki, N., Tooley, K., Presumey, J., Baum, M., Van Doren, V., et al. (2016) · Nature · doi:10.1038/nature16549 · Cited by 2,394 · cited 1×
“Synaptopathy, change and/or abnormality in the function and structure of synapses, has been frequently observed in patients with neurodegenerative disorders including Alzheimer’s disease (AD) [1, 2], Parkinson’s disease (PD) [3], and epilepsy [4, 5], as well as psychiatric diseases such as depression [6], schizophreni…”
BackgroundDecreased Dendritic Spine Density on Prefrontal Cortical Pyramidal Neurons in Schizophrenia
Glantz, L. A., & Lewis, D. A. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.1.65 · Cited by 1,636 · cited 1×
“Synaptopathy, change and/or abnormality in the function and structure of synapses, has been frequently observed in patients with neurodegenerative disorders including Alzheimer’s disease (AD) [1, 2], Parkinson’s disease (PD) [3], and epilepsy [4, 5], as well as psychiatric diseases such as depression [6], schizophreni…”
BackgroundThe synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam
Lynch, B. A., Lambeng, N., Nocka, K., Kensel-Hammes, P., Bajjalieh, S. M., Matagne, A., & Fuks, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308208101 · Cited by 1,610 · cited 1×
“It has also been identified as the binding site of the anti-epileptic drugs levetiracetam and brivaracetam [13].”
BackgroundEnhancement of MR Images Using Registration for Signal Averaging
Holmes, C. J., Hoge, R., Collins, L., Woods, R., Toga, A. W., & Evans, A. C. (1998) · Journal of Computer Assisted Tomography · doi:10.1097/00004728-199803000-00032 · Cited by 1,417 · cited 2×
“The summed PET image was then co-registered to the subject’s T1weighted MR image (6-parameter affine registration), which was subsequently co-registered to the automated anatomical labeling (AAL) template [30] in Montreal Neurological Institute (MNI) [31] space using a nonlinear transformation (Bioimage suite) [32].”
MethodStabin, M. G., Sparks, R. B., & Crowe, E. A. (2005) · PubMed · Cited by 1,350
Loss of mTOR-Dependent Macroautophagy Causes Autistic-like Synaptic Pruning Deficits
Tang, G., Gudsnuk, K., Kuo, S.-H., Cotrina, M. L., Rosoklija, G., Sosunov, A., Sonders, M. S., Kanter, E., Castagna, C., Yamamoto, A., et al. (2014) · Neuron · doi:10.1016/j.neuron.2014.07.040 · Cited by 1,146 · cited 1×
“Synaptopathy, change and/or abnormality in the function and structure of synapses, has been frequently observed in patients with neurodegenerative disorders including Alzheimer’s disease (AD) [1, 2], Parkinson’s disease (PD) [3], and epilepsy [4, 5], as well as psychiatric diseases such as depression [6], schizophreni…”
BackgroundDecreased expression of synapse-related genes and loss of synapses in major depressive disorder
Kang, H. J., Voleti, B., Hajszan, T., Rajkowska, G., Stockmeier, C. A., Licznerski, P., Lepack, A., Majik, M. S., Jeong, L. S., Banasr, M., et al. (2012) · Nature Medicine · doi:10.1038/nm.2886 · Cited by 808 · cited 1×
“Synaptopathy, change and/or abnormality in the function and structure of synapses, has been frequently observed in patients with neurodegenerative disorders including Alzheimer’s disease (AD) [1, 2], Parkinson’s disease (PD) [3], and epilepsy [4, 5], as well as psychiatric diseases such as depression [6], schizophreni…”
BackgroundSpecific absorbed fractions of energy at various ages from internal photon sources: 6, Newborn
Cristy, M., & Eckerman, K. F. (1987) · doi:10.2172/6202949 · Cited by 692
Imaging synaptic density in the living human brain
Finnema, S. J., Nabulsi, N. B., Eid, T., Detyniecki, K., Lin, S.-F., Chen, M.-K., Dhaher, R., Matuskey, D., Baum, E., Holden, D., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6667 · Cited by 575 · cited 1×
“The decreased binding corresponded well with previous tissue analysis, and the binding asymmetry was more specifically localized to the seizure onset zone (SOZ), while the change in [(18)F]FDG uptake also extended to the adjacent regions [14].”
BackgroundSelf-citation
Research works printed but not linked: 1
- Carson RE, Barker W, Liow J-S, Adler S, Johnson C. Design of a motion-compensation OSEM list-mode algorithm for resolution-recovery reconstruction of the HRRT. IEEE Nucl Sci Symp Conf Rec. 2003:M16–6.
Cited by
Radiopharmaceuticals and their applications in medicine
Zhang, S., Wang, X., Gao, X., Chen, X., Li, L., Li, G., Liu, C., Miao, Y., Wang, R., & Hu, K. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02041-6 · Cited by 284
Synaptic Vesicle Glycoprotein 2A: Features and Functions
Rossi, R., Arjmand, S., Bærentzen, S. L., Gjedde, A., & Landau, A. M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.864514 · Cited by 123
“Several [18F]-labeled candidates have now been evaluated (Patel et al., 2020), especially UCBJ derivatives including [18F]MNI-1126 (Constantinescu et al., 2019), also named [18F]-SDM-8 and described by Li et al. (2019a) and then referred as [18F]-SynVesT-1 (Li et al., 2021; Naganawa et al., 2021b).”
MethodImaging of Synaptic Density in Neurodegenerative Disorders
Carson, R. E., Naganawa, M., Toyonaga, T., Koohsari, S., Yang, Y., Chen, M.-K., Matuskey, D., & Finnema, S. J. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263201 · Cited by 104
“Excellent test–retest reproducibility and low-noise VT images can be obtained with the 1TC model for (11)C-UCB-J (37) and (18)F-SynVesT-1 (31,32).”
BackgroundMethodSelf-citationRibarič, S. (2023) · Biomedicines · doi:10.3390/biomedicines11020355 · Cited by 66
Tang, Y., Yu, J., Zhou, M., Li, J., Long, T., Li, Y., Feng, L., Chen, D., Yang, Z., Huang, Y. H., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05665-w · Cited by 38
“Compared to 11C-UCB-J, the newly reported SV2A radioligand 18F-SynVesT-1 has a longer half-life and superior signal-to-noise ratio [14, 15].”
Self-citationSynaptic changes in psychiatric and neurological disorders: State-of-the art of in vivo imaging
Howes, O., Marcinkowska, J., Turkheimer, F. E., & Carr, R. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-024-01943-x · Cited by 34
“6 [ 30 ] 5 – 20 m i n s [ 35 ] 2021 [ 35 ] 9 % [ 34 ] [ 18 F ] S y nV e s t - 2 9 .”
MethodZheng, C., Holden, D., Zheng, M.-Q., Pracitto, R., Wilcox, K. C., Lindemann, M., Felchner, Z., Zhang, L., Tong, J., Fowles, K., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05597-5 · Cited by 35
“We have previously reported the synthesis and evaluation of a series of fluorine-18-labeled SV2A PET tracers, which all showed excellent brain imaging properties, and some have been translated into first-in-human studies [37, 42, 43].”
BackgroundMethodSelf-citationSV2A PET imaging in human neurodegenerative diseases
Bavarsad, M. S., & Grinberg, L. T. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1380561 · Cited by 39
Cervenka, S., Frick, A., Bodén, R., & Lubberink, M. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-01990-2 · Cited by 32
“[11C]UCB-J has been applied in patients with MDD and/or PTSD, showing an inverse correlation between depressive symptoms and SV2A density, as well as an association between SV2A density and functional connectivity in prefrontal cortex as measured using resting-state functional MR (fMRI) [32].”
BackgroundInfluentialBertoglio, D., Zajicek, F., Lombaerde, S. D., Miranda, A., Stroobants, S., Wang, Y., Dominguez, C., Munoz-Sanjuan, I., Bard, J., Liu, L., et al. (2022) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x221101648 · Cited by 29
“[(18)F] SynVesT-1 quantification displayed high stability in the outcome parameter estimation, reflecting the possibility of reducing scan acquisition down to 60min, with <3% of deviation from the 120-min acquisition and consistent with the observation in humans.(19) Comparison of 2TCM to Logan plot demonstrated the v…”
MethodResultInfluentialVisser, M., O’Brien, J. T., & Mak, E. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102197 · Cited by 28
“In comparison to [ 11 C]UCB-J, absolute TRT reproducibility for [ 18 F]SynVesT-1 (performed 7 ± 7 days apart) was similar for V T and slightly less for BP ND across regions, with values of 9% (Li et al., 2021).”
BackgroundMethodPET Imaging in Animal Models of Alzheimer’s Disease
Chen, B., Marquez-Nostra, B. V., Belitzky, E., Toyonaga, T., Tong, J., Huang, Y. H., & Cai, Z. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.872509 · Cited by 32
Self-citationSynaptic Density in Early Stages of Psychosis and Clinical High Risk
Blasco, M. B., Aji, K. N., Ramos-Jiménez, C., Leppert, I. R., Tardif, C. L., Cohen, J. P., Rusjan, P., & Mizrahi, R. (2024) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2024.3608 · Cited by 23
Toyonaga, T., Fesharaki-Zadeh, A., Strittmatter, S. M., Carson, R. E., & Cai, Z. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.787404 · Cited by 20
“There are several 18F-labeled SV2A tracers, i.e., [18F]UCBH (Warnock et al., 2014), [18F]UCB-J (Li et al., 2019b), [18F]SynVesT-1 (Li et al., 2019a, 2021), [18F]SynVesT-2 (Cai et al., 2020b), and [18F]SDM-16 (Zheng et al., 2021), with different specific binding, brain kinetics, and peripheral…”
BackgroundSelf-citationDrake, L. R., Wu, Y., Naganawa, M., Asch, R., Zheng, C., Najafzadeh, S., Pracitto, R., Lindemann, M., Li, S., Ropchan, J., et al. (2024) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.266470 · Cited by 18
Self-citationSmart, K. A., Uribe, C., Desmond, K. L., Martin, S. L., Vasdev, N., & Strafella, A. P. (2023) · Molecular Imaging · doi:10.1155/2023/1855985 · Cited by 18
Xiao, L., Yang, J., Zhu, H., Zhou, M., Li, J., Liu, D., Tang, Y., Feng, L., & Hu, S. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06593-1 · Cited by 16
“As a specific radioligand for SV2A, [ 18 F]SynVesT-1 has been employed in the investigation of several neuropsychiatric diseases, especially epilepsy [13, 30–32].”
Noninvasive quantification of [18F]SynVesT-1 binding using simplified reference tissue model 2
Naganawa, M., Gallezot, J., Li, S., Nabulsi, N., Henry, S. E., Cai, Z., Matuskey, D., Huang, Y. H., & Carson, R. E. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06885-6 · Cited by 16
Self-citationAsch, R. H., Abdallah, C. G., Carson, R. E., & Esterlis, I. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-024-01913-3 · Cited by 13
Self-citationXiao, L., Xiang, S., Chen, C., Zhu, H., Zhou, M., Tang, Y., Feng, L., & Hu, S. (2024) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13682 · Cited by 14
“We aimed to test the hypothesis that synaptic density, as assessed by [ 18 F]SynVesT-1 PET in patients and the rat model of TLE, is associated with cognitive impairment, which could be reversed by chronic treatment with LEV.”
InfluentialLi, R., Xiao, L., Han, H., Long, H., Liao, W., Yang, Z., Zhu, H., Wang, X., Zou, T., Huang, Y., et al. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-07054-5 · Cited by 14
“…production and distribution to multi-center clinical studies, Naganawa et al. developed a novel 18 F-labeled radiotracer, [ 18 F]SynVesT-1, with feasibility for translation to clinical diagnostic applications and have recently demonstrated its excellent kinetics and high brain uptake [33, 34].”
Self-citationImaging Synaptic Density in Aging and Alzheimer Disease with [ 18 F]SynVesT-1
Giorgio, J., Soleimani‐Meigooni, D. N., Janabi, M., Baker, S. L., Chen, X., Toueg, T. N., Weimer, R. M., Zinnhardt, B., Green, A., Rabinovici, G. D., et al. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.269005 · Cited by 14
Kong, Y., Zhang, S., Huang, L., Zhang, C., Xie, F., Zhang, Z., Huang, Q., Jiang, D., Li, J., Zhou, W., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.731114 · Cited by 13
“Therefore, [18F]SynVesT-1 is expected to be an excellent SV2A tracer for clinical imaging and quantification of humans (Li et al., 2019c, 2021; Naganawa et al., 2020).”
BackgroundHusain, M. O., Jones, B., Arshad, U., Ameis, S. H., Mirfallah, G., Schifani, C., Rodak, T., Aiken, M., Shafique, M. S., Ahmed, F., et al. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-05788-y · Cited by 10
Dahl, K., Larsson, S., Bonn, P., Wallin, A., Itsenko, O., & Schöll, M. (2022) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.4002 · Cited by 9
Isoflurane and ketamine-xylazine modify pharmacokinetics of [ 18 F]SynVesT-1 in the mouse brain
Miranda, A., Bertoglio, D., Weerdt, C. D., Staelens, S. G., & Verhaeghe, J. A. J. (2023) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x231173185 · Cited by 9
“central nervous system synaptic density and presents high specific binding and excellent test-retest reproducibility in humans.(3) SV2A tracers have been used for example in research on epilepsy(4) and Alzheimer’s disease.”
MethodAn overview: Radiotracers and nano-radiopharmaceuticals for diagnosis of Parkinson's disease
Ozolmez, N., Silindir‐Gunay, M., & Salancı, B. V. (2023) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2023.111110 · Cited by 8
Chen, B., Zheng, C., Balayeva, T., Toyonaga, T., Wang, X., Tong, J., Mennie, W., Mihailovic, J. M., Coman, D., Hyder, F., et al. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.269291 · Cited by 10
“In this study, we used the newly developed 18 F-labeled SV2A radiotracer, [ 18 F]SynVesT-1 ( 20 , 26 – 28 ), to assess changes in synaptic density in a rat model of T7 contusion ( 17 ).”
Self-citationSynaptic density patterns in early Alzheimer’s disease assessed by independent component analysis
Fang, X. T., Raval, N. R., O’Dell, R. S., Naganawa, M., Mecca, A. P., Chen, M.-K., van Dyck, C. H., & Carson, R. E. (2024) · Brain Communications · doi:10.1093/braincomms/fcae107 · Cited by 7
Self-citationVanderlinden, G., Carron, C. P., Vandenberghe, R. R., Vandenbulcke, M., & Laere, K. V. (2024) · BMC Medical Imaging · doi:10.1186/s12880-024-01224-5 · Cited by 7
“[52]; and a non-inferiority margin of 10%, assuming an α-level of 0.025 and a statistical power of 80%, the required sample size is 8 patients, of no ‘true’ difference.”
BackgroundMethodInfluential18F-SynVesT-1 PET in Focal Cortical Dysplasia Type II With Thickening Cortex
Tang, Y., Yu, J., Zhou, M., Chen, C., & Hu, S. (2022) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000004214 · Cited by 6
Berckmans, L., Schrauwen, C., Miranda, A., Staelens, S. G., & Bertoglio, D. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07170-w · Cited by 6
Chen, L., Li, X., Ge, Y., Li, H., Li, R., Song, X., Liang, J., Zhang, W., Li, X., Wang, X., et al. (2024) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-024-00284-w · Cited by 6
“Under the condition, the retention time of [ 18 F] Syn-VesT-1 was approximately 19 min (1140 s) (Fig.”
Asch, R., Naganawa, M., Nabulsi, N., Huan, Y., Esterlis, I., & Carson, R. E. (2023) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x231200423 · Cited by 5
“26 Additionally, the B/I approach examined here produce similar BP ND estimates to that of bolus studies.”
ResultSelf-citation18F‐SynVesT ‐1 positron emission tomography in a hypothalamic hamartoma with abnormal uptake
Xiao, L., Zhou, M., Tang, Y., & Hu, S. (2023) · Epilepsia · doi:10.1111/epi.17533 · Cited by 5
Positron Emission Tomography (PET) Imaging Biomarkers in Huntington’s Disease
Everix, L., Staelens, S. G., & Bertoglio, D. (2023) · Contemporary clinical neuroscience · doi:10.1007/978-3-031-32815-2_6 · Cited by 4
Luan, Y., Huang, Q., Wang, J., Guan, Y., Li, B., Franzmeier, N., Xie, F., & Ewers, M. (2025) · Brain · doi:10.1093/brain/awaf425 · Cited by 5
Li, J., Chen, D., Tang, Y., Zhao, C., Zhou, M. S., Wan, L., Xiao, L., Fu, Y., He, Z., Tang, Z., et al. (2025) · Annals of Neurology · doi:10.1002/ana.27179 · Cited by 3
“PET images were acquired approximately 60 minutes after intravenous injection of [ 18 F]SynVesT-1 (3.7 MBq/kg) for 30 minutes, using a PET/computed tomography (CT) scanner (GE Healthcare).”
InfluentialAsch, R., Naganawa, M., Moisieienko, K., Weed, M., Kapinos, M., Zheng, M., Hillmer, A. T., Carson, R. E., Pietrzak, R. H., & Esterlis, I. (2025) · EJNMMI Research · doi:10.1186/s13550-025-01200-2 · Cited by 2
Self-citationSchrauwen, C., Halloin, N., Eetveldt, A. V., Laermans, Z., Vos, W. H. D., Jankovski, A., Verhoye, M., Staelens, S. G., Nicaise, C., & Bertoglio, D. (2026) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.271236 · Cited by 2
Hernández‐Martín, N., Balayeva, T., Naganawa, M., Asch, R., Huang, Y. H., Carson, R. E., Gallezot, J., & Cai, Z. (2026) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.271207 · Cited by 3
“The gold standard for analyzing SV2A brain PET data involves the use of a metabolite-corrected arterial input function (AIF) ( 16 , 17 , 19 ).”
Self-citationAssessment of test-retest reproducibility by [18F]Bavarostat for PET imaging of HDAC6
Naganawa, M., Zheng, M., Gallezot, J., Bonomi, R. E., Gu, J., Gao, H., Jacutin-Porte, S., Nabulsi, N., Koole, M., Laere, K. V., et al. (2025) · EJNMMI Research · doi:10.1186/s13550-025-01268-w · Cited by 2
“…is common for PET test-retest studies in human participants ([ 18 F] Bavarostat, n = 4, 1-day apart [18]; [ 18 F]SynVesT-1, n = 6, 7 ± 7 days apart [26]; 6-bromo-7-[ 11 C]methylpurine, n = 6, 20 ± 10 days apart [27]; [ 18 F]FPEB, n = 9, 6-month apart [28]), a larger sample would provide more…”
Self-citationPotential of [11C]UCB-J as a PET tracer for islets of Langerhans
Puuvuori, E., Rokka, J., Carlsson, P., Li, Z., Eriksson, J., & Eriksson, O. (2021) · Scientific Reports · doi:10.1038/s41598-021-04188-6 · Cited by 1
Qin, L., Chen, B., Xiao, L., Zhu, H., Hou, M., Long, X., Tang, W., Zhang, X., Qv, M., Tang, Y., et al. (2025) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2025.110826 · Cited by 1
Asch, R., Martin, N. H., García-Milian, R., Fowles, K., Dileone, R., Cai, Z., Liston, C. M., & Esterlis, I. (2025) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2025.09.021 · Cited by 2
Self-citationUribe, C., Narciso, L., Cho, S. S., Zilberman, M., Cote, C., Yu, L., Truong, J. T., Dickie, E. W., Nikolova, Y. S., Voineskos, A. N., et al. (2026) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-026-07818-1 · Cited by 1
“[¹⁸F]SynVesT-1 (a.k.a. [ 18 F]SDM-8) has emerged as a promising tool for SV2A quantification due to its lon - ger half-life and strong binding affinity, offering practical advantages over 11 C-labelled alternatives such as [¹¹C] UCB-J [6, 7].”
A brief review of the neuroimaging modalities in schizophrenia and their scope
Ray, S., Pal, A. K., & Kundu, P. S. (2024) · Annals of Medical Science and Research · doi:10.4103/amsr.amsr_52_23 · Cited by 1
Synaptic PET Imaging in Neurodegeneration
Chen, M., Matuskey, D., Finnema, S. J., & Carson, R. E. (2023) · Springer eBooks · doi:10.1007/978-3-031-35098-6_10 · Cited by 1
Self-citationApplication of SV2A PET in neurodegenerative disorders
Chen, D., & JIANG, H. (2024) · Scientia Sinica Vitae · doi:10.1360/ssv-2024-0086
Fluid and Imaging Markers of Synaptic Injury
Tarawneh, R. M. (2025) · Springer eBooks · doi:10.1007/978-3-031-80849-4_4
Soleimani‐Meigooni, D. N., & Rabinovici, G. D. (2025) · Cambridge University Press eBooks · doi:10.1017/9781108985055.006
Husain, M. O., Jones, B. D. M., Arshad, U., Ameis, S. H., Mirfallah, G., Schifani, C., Rodak, T., Aiken, M., Shafique, M., Ahmed, F., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26066220
Husain, M. O., Jones, B., Arshad, U., Ameis, S. H., Mirfallah, G., Schifani, C., Rodak, T., Aiken, M., Shafique, M., Ahmed, F., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26736453
Husain, M. O., Jones, B., Arshad, U., Ameis, S. H., Mirfallah, G., Schifani, C., Rodak, T., Aiken, M., Shafique, M., Ahmed, F., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26066140
Panichnantakul, P., Shaw, R., Burianova, V. K., McErlain, H., Sutherland, A., Williams, A., Waldman, A. D., & Tavares, A. A. S. (2026) · EJNMMI Research · doi:10.1186/s13550-026-01391-2
“In particular, [ 18 F]SynVestT-1 has displayed excellent imaging and binding characteristics across various species, including mice, rats, non-human primates, and humans [5–9].”
Everix, L., Miranda, A., Akkermans, J., Khetarpal, V. K., Liu, L., Bard, J., Staelens, S. G., & Bertoglio, D. (2026) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x261435323
Psilocybin’s effect on human brain synaptic plasticity
Johansen, A., Plavén‐Sigray, P., Madsen, M. K., Søndergaard, A., Messell, C., Geisler, M., Nasser, A., McCulloch, D. E.-W., Beliveau, V., Vassilieva, A., et al. (2026) · Translational Psychiatry · doi:10.1038/s41398-026-04285-y · Cited by 1
“We show that the psychedelic experience is shaped by the session environment and present the fi rst evidence that synaptic plasticity may be enhanced when the intervention takes place in a setting that facilitates mystical-type experiences.”
Carron, C. P., Noë, S., Vanderlinden, G., Koole, M. J. B., Schramm, G., & Laere, K. V. (2026) · EJNMMI Research · doi:10.1186/s13550-026-01496-8
“Nevertheless, these regions have proven to provide reproduceable (absolute test-retest variability in distribution volume of 4% for CER and 7% of CSO) [11] and useful quantitative information in HV and AD [12–14] as pseudo-reference regions.”
Hehl, M., Toyonaga, T., Carson, R. E., Dupont, P. J., Laere, K. V., Swinnen, S. P., & Cuypers, K. (2026) · npj Science of Learning · doi:10.1038/s41539-026-00451-5
Self-citationNovel Radiotracers in PET Imaging
Gimblet, G. R., & Lapi, S. E. (2026) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2026.08.011
Honhar, P., Tinaz, S., Sadabad, F. E., Gallezot, J., Naganawa, M., Dias, M., Ye, Y., Gao, H., Nabulsi, N., Huang, Y. H., et al. (2026) · medRxiv · doi:10.64898/2026.09.28.26364237
Self-citationCarron, C., Boeckxstaens, L., Degryse, L., Vanderlinden, G., Noë, S., Deckers, W., Schramm, G., Gijs, J., Vandenbulcke, M., Vandenberghe, R., et al. (2026) · Journal of Nuclear Medicine · doi:10.2967/jnumed.126.272646
Metadata
- Authors
- Li, S., Naganawa, M., Pracitto, R., Najafzadeh, S., Holden, D., Henry, S., Matuskey, D., Emery, P. R., Cai, Z., Ropchan, J., Nabulsi, N., Carson, R. E., & Huang, Y.
- Affiliations
- Yale University (US)
- Corresponding author
- Li, Songye
- Huang, Yiyun
- ORCID
- Venue
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2021-01-08
- Volume
- 48
- Issue
- 5
- Pages
- 1327-1338
- ISSN
- 1619-7070 (ISSN-L)
- 1619-7089
- OpenAlex
- W3118626742
- Cited by
- 61
- References
- 35
- Citations by year
- 2026: 8 · 2025: 14 · 2024: 19 · 2023: 8 · 2022: 9 · 2021: 3
- FWCI
- 5.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- European Journal of Nuclear Medicine and Molecular Imaging (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (R01AG052560, R01AG065474)
- Michael J. Fox Foundation for Parkinson's Research
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- [18F]SynVesT-1, SV2A, test-retest reproducibility, dosimetry, non-human primates, rhesus monkeys, [11C]UCB-J, binding potential, volume of distribution, time-activity curves, one-tissue compartment model, brain uptake
- MeSH terms
- Animals, Brain, Fluorine Radioisotopes, Glycoproteins, Pyridines, Pyrrolidinones, Synaptic Vesicles, Reproducibility of Results, Radiopharmaceuticals, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.